在BCR::ABL1-阴性髓增殖性瘤的爆发阶段的基因组变化
1Department of Pathology and Laboratory Medicine, UConn Health, Farmington, Connecticut, USA.
International journal of laboratory hematology
|October 23, 2023
概括
在BCR::ABL1-阴性骨髓增殖新生体爆发期 (MPN-BP) 的遗传突变驱动疾病的进展. 了解这些复杂的基因组变化是管理MPN这一高级阶段的关键.
科学领域:
- 血液学 血液学 血液学
- 基因组学就是基因组学.
- 分子生物学分子生物学
背景情况:
- BCR::ABL1-阴性骨髓扩散性新生瘤 (MPN-BP) 的爆发阶段是复杂的基因组改变的关键,高级阶段.
- 这些变化涉及遗传物质 (DNA,RNA) 的变化,影响蛋白质功能和细胞过程.
研究的目的:
- 审查MPN-BP中常见的突变概况.
- 为了阐明这些突变基因的功能.
- 探索它们与MPN-BP进展的关联.
主要方法:
- 对MPN-BP的遗传变异研究的文献综述.
- 对基因突变数据和功能影响的分析.
- 突变与疾病进展之间的相关性分析.
主要成果:
- 确定了关键的突变基因,包括ASXL1,EZH2,IDH1/2,TET2,SRSF2,U2AF1,TP53,NRAS/KRAS,PTPN11,SH2B3/LNK,以及RUNX1.
- 这些突变会影响基因表达,蛋白质功能和细胞信号传递的各个阶段.
- 突变与MPN-BP进展有显著的相关性,并有助于其进展.
结论:
- 特定的基因突变在MPN-BP的发病和进展中起着至关重要的作用.
- 了解这些突变格局对于开发向疗法和改善高级MPN患者的治疗结果至关重要.
关键词:
美国证券交易所ASXL1在 EZH2 中使用.一个IDH1一个IDH1在IDH2中,它是IDH2.克拉斯 (Kras) 是一个国家.它们是NRAS和NRAS.在PTPN11中,在RUNX1中,使用RUNX1.在SH2B3/LNK中.在 SRSF2 基金中,在TET2的基础上.这就是TP53的特点.这就是U2AF1AF1.骨髓扩散性瘤的爆发阶段更多相关视频
09:49Oncogenic Gene Fusion Detection Using Anchored Multiplex Polymerase Chain Reaction Followed by Next Generation Sequencing
Published on: July 5, 2019
9.6K
09:01Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
Published on: March 26, 2018
14.0K
相关概念视频
02:23Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
02:57Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K